Sandoz Strengthens Market Presence With Launch Of Pyzchiva (Ustekinumab) Biosimilar Across Europe
Portfolio Pulse from Benzinga Newsdesk
Sandoz has launched Pyzchiva (ustekinumab) biosimilar across Europe to treat chronic inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and pediatric plaque psoriasis. This launch strengthens Sandoz's immunology portfolio in Europe.
July 25, 2024 | 6:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sandoz's launch of Pyzchiva (ustekinumab) biosimilar across Europe is likely to strengthen its market presence and boost revenues in the immunology sector.
The launch of Pyzchiva, the first ustekinumab biosimilar in Europe, is a significant milestone for Sandoz. It enhances their product portfolio and is expected to drive revenue growth in the immunology market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100